To overcome difficulties that hampered widespread application of a specific delivery system in cancer gene therapy and to inhibit the growth of solid liver cancer, we utilized a strain of Bifidobacterium longum as a delivery system to transport an endostatin gene that can inhibit growth of tumor. The B. longum strain with the endostatin gene (B. longum-En) was taken orally by tumor-bearing nude mice through drencher preparation. The results showed that B. longum-En could strongly inhibit the growth of solid liver tumor in nude mice and prolong the survival time of tumor-bearing nude mice. Furthermore, tumor growth was inhibited more efficiently when the B. longum-En treatment included selenium. Enriching the B. longum-En treatment with selenium improves the activity of NK and T cells and stimulates the activity of IL-2 and TNF-a in BALB/c mice. These results suggest that B. longum may be a highly specific and efficient vector for transporting anticancer genes in cancer gene therapy.
U ncontrolled tumor growth is one of the leading causes of death. Tumor progression and metastasis requires angiogenesis. O'Reilly et al 1 found a new antiangiogenesis factor, endostatin, which is the COOHterminal part of the collagen XVIII a1-chain in the tumor cell of mice. Endostatin has been shown to regress a range of model tumors. Endostatin significantly reduces angiogenesis and metastasis in a number of known cancer types without side effects in mice, including Lewis lung cancer, T241 fiber sarcoma, B16-F10 melanoma, ovary cancer, liver cancer and others. It can inhibit angiogenesis and metastasis in these tumors without any toxicity and side effect to animals. [2] [3] [4] [5] It can also inhibit abnormal proliferation of endothelial cells and provoke the apoptosis of tumor cells. This is especially apparent when accompanied with radiotherapy, chemotherapy and other antiangiogenesis preparations. 6, 7 Bifidobacterium adolescentis and Bifidobacterium longum can both selectively germinate and grow in the hypoxic regions of solid tumors following intravenous injection. 8, 9 Our previous study had shown that B. adolescentis could be used as a delivery system of endostatin to inhibit angiogenesis and hypoxic tumor growth selectively. 9 Many studies also have shown that Bifidobacterium can germinate and grow in the lower small intestines of animals and humans without any toxicity or side effect. [10] [11] [12] B. longum is a strain of half-anaerobic Bifidobacterium. There are more living bacteria of B. longum than B. adolescentis that can survive freeze-drying. In the present study, we selected a strain of B. longum as the delivery system to transport endostatin to animal's intestines directly, 13 and then evaluated the actions of B. longum as a vector of antitumor gene in liver cancer therapy.
Materials and methods

Animals
Male nude mice and BALB/c mice (from Animal Center, Nanjing Medical University, Nanjing, China, weighing 2072 g) were used in this study. Mice were fed standard rodent diet.
Tumors
HepG2 human liver cancer, 14 Yac-1 mouse lymphoma sensitive to NK cell 15 and L929 human fibre cell sensitive for TNF-a 16 (from Cell Center of Chinese Academy of Medicine, Beijing, China) were maintained as a monolayer culture in PRMI-1640 medium supplemented with 10% fetal bovine serum at 371C, 5% CO 2 . Heps mouse liver cancer 17 tissues were minced thoroughly to obtain cancer cells. A total of 1 Â 10 6 cancer cells adjusted to 5 Â 10 6 cell/mL were inoculated under the skin of the right thigh for each mouse.
Plasmid construction and transformation to B. longum B. longum 18 was obtained from the Chinese IFFI Microbial Center and anaerobically cultured at 371C in TPY medium. A shuttle vector, pBV220, 19 obtained from the Institute of Virology, Chinese Academy of Preventive Medicine, was employed in this study. Human endostatin gene was amplified from human liver cDNA library (from Clontech, Franklin Lakes, NJ) and inserted into pBV220 vector. The recombinant plasmid was purified with QIAprep spin miniprep kit (from Qiagen, Hilden, Germany).
Expression and Western blot analysis of endostatin in B. longum-En B. longum-En were incubated at 301C for 12 hours, and then stimulated at 421C for 6 hours when OD 600 reached 0.5-0.7 after diluting in about 1/50 of fresh TPY medium. The detail of the SDS-PAGE and Western blot analysis are presented elsewhere. 9 Plasmid of pBV220/endostatin in B. longum-En shuttle into other bateria Ampicillin-sensitized bacteria (Staphylococcus aureus, Staph. albus, Staph. citreus, Beta Streptococcus, Gamma Streptococcus, Salmonella, Escherichia coli DH 5a , E. coli BL 21 DE 3 ) and B. longum-En were cultured separately at 371C to middle log phase in TPY medium. Then ampicillin-sensitized Staph. aureus, Staph. albus, Staph. citreus, Beta Streptococcus, Gamma Streptococcus, Salmonella, E. coli DH 5a or E. coli BL 21 DE 3 was then cultured anaerobically with B. longum-En in TPY medium at 371C for 18 hours. Ampicillin (100 mg/mL final concentration) was added to solidified culture medium (1.5% agar) below 551C, then the medium was poured into dishes at 16 mL/dish at room temperature. After the agar medium was solidified, the mixtures (20 mL/dish) of the two bacteria were mixed thoroughly on the surfaces of the dishes and incubated aerobically at 371C for 24 hours. Thereafter, the number of colonies on per dish was counted to determine the number of transferred pBV220-Endostatin plasmids.
Treatment of tumor-bearing nude mice with B. longum-En B. longum and B. longum-En cultures were washed three times with phosphate-buffered saline (PBS) (pH 7.4) before taking orally. The HepG2 tumor-bearing nude mice were divided into two groups. Group 1 was divided into four subgroups, B. longum-En group (1.5 Â 10 10 bacteria/kg), B. longum group (1.5 Â 10 10 bacteria/kg), PBS-negative control group (0.4 mL/mice) and cyclophosphamide-positive control group (10 mg/kg). Group 2 was also divided into four subgroups as described above. After 18 days of treatment, the mice of group 1 were killed and the tumor were excised and weighed. The inhibition level of tumor growth was determined by the following formula:
tumor weight of control group À tumor weight of treatment group tumor weight of control group Â100%
And the mice of group 2 were fed standard rodent diet and the survival times of the mice were recorded. The level of prolong life time was determined by average life time of treatment group À average life time of control group average life time of control group Â100%
Nervous system of BALB/c mice were affected by treating with B. longum-En
Male BALB/c mice were divided into three groups: (1) a B. longum-En group (1.5 Â 10 10 bacteria/kg), (2) a B. longum group (1.5 Â 10 10 bacteria/kg), and (3) a PBS control group (0.4 mL/mice). After 1 h following oral ingestion of the bacteria and PBS, the following attributes were recorded: the surface, hair, pose, and the walking action of the animals, narcosis, hypnosis, sedation, muscle tremor, eye vibrations, and pupil change. In addition, one animal of each group was put into a so-called ''Freedom Action Procedure Instrument'' (Institute of Pharmacy, Chinese Academy of Medicine). The animals' free movements were recorded for 3 minutes. These experiments were conducted over a 7-day period.
Enrichment of selenium to B. longum-En (Se-B. longum-En) B. longum-En was cultured in TPY medium supplemented with 0, 0.25, 0.5 and 5 mg/mL of sodium selenite and incubated at 371C for 18 hours, then washed with PBS for three times. The concentrations of selenium in Se-B. longum-En were measured with fluorescent spectrophotometry analysis. 20 The tumor growth inhibition test of Se-B. longum-En was carried out as described above.
Killing activity of NK cell provoked by treating with Se-B. longum-En
Heps tumor-bearing BALB/c mice were divided into five subgroups according to dosages: (1) PBS control, (2) middle dose of B. longum-En (1.5 Â 10 10 bacteria/kg), (3) high dose of Se-B. longum-En (3 Â 10 10 bacteria/kg), (4) middle dose of Se-B. longum-En (1.5 Â 10 10 bacteria/kg) and (5) low dose of Se-B. longum-En (0.75 Â 10 10 bacteria/kg). This treatment was carried out for 15 continuous days. After 18 days of treatment, the eye-pit blood serum of the mice was obtained for the subsequent experiment. The mice were then killed and spleens were excised. The spleen cells were obtained as effect cells at a concentration of 1 Â 10 6 cells/mL. The effect cells (200 mL/ well) were incubated in RPMI 1640 with 10% fetal bovine serum in 96-well plate at 371C, 5% CO 2 . Yac-1 mouse lymphoma sensitive to NK cells were obtained as target cells at a concentration of 1 Â 10 6 cells/mL. The target cells (200 mL/well) were incubated in RPMI 1640 with 10% fetal bovine serum in a 96-well plate. Additionally, 100 mL effect cell and 100 mL target cell were mixed thoroughly and inoculated in 96-well plate. After 72 hours of culture, 10 mL MTT (5 mg/mL) was added to each well. At 4 hours after culture, 150 mL DMSO was added to each well. The OD 540 nm value was then measured. The killing activity of NK cell was determined by the following formula:
OD 540nm effect cell þ OD 540nm target cell À OD 540nm value of mixture OD 540nm value of effect cell þ OD 540nm value of target cell Â100%
Proliferation of T cell enhanced by treating with Se-B. longum-En
The spleens of the healthy BALB/c mice were excised. The spleen cells were prepared and adjusted to a concentration of 2 Â 10 6 cells/mL. A volume of 100 mL spleen cells was incubated in RPMI 1640 with 10% fetal bovine serum in 96-well plate at 371C, 5% CO 2 . Following this, 100 mL serum of mice (from the different groups described above) and 5 mg/mL concanavalin A (final concentration) were added to each well. After 72 hours of incubation, the OD 540 nm value was measured with MTT method.
Activity of IL-2 improved in mouse by treating with Se-B. longum-En
The thymus glands of healthy BALB/c mice were excised. The thymocytes were obtained and adjusted to a concentration of 2 Â 10 6 cells/mL. A volume of 100 mL thymocytes was incubated in RPMI 1640 with 10% fetal bovine serum in 96-well plate at 371C, 5% CO 2 . Following this, 100 mL serum of mice from different groups as described above and 5 mg/mL concanavalin A (final concentration) were added to each well. After 72 hours of incubation, the OD 540 nm value was measured with MTT method.
Activity of TNF-a promoted by treating with Se-B. longum-En L929 human fiber cells sensitive for TNF-a were incubated in RPMI 1640 with 10% fetal bovine serum in 96-well plate at 371C, 5% CO 2 . The cell number was adjusted to 2 Â 10 5 cells/well. Then, 100 mL serum of mice from different groups as described above and 1 mg/mL dactinomycin were added into each well and incubated overnight. The blank control wells were set simultaneously. The OD 540 nm value was measured with MTT method. The death ratio was determined by the following formula:
OD 540nm value of control group À OD 540nm value of experimental group OD 540nm value of control group Â100%
Data analysis
Each test was performed in 10 duplicates. The data were statistical analyzed by using the Student's t-test and P-value of o0.05 were considered to be significant. The results were represented as mean7SD value.
Results
Expression of endostatin in B. longum-En
The expression of endostatin in B. longum-En was assayed by Western blot analysis using a monoclonal mouse antihuman endostatin antibody. Recombinant endostatin protein (of about 20 kDa) was used as the positive control. A band of similar size was also observed from B. longum-En. There was no positive antibody reactivity band from normal B. longum (Fig 1) .
PBV220/endostatin plasmid in B. longum-En transferring to other bacteria 
Inhibition of B. longum-En to the growth of primary tumors in nude mice
To determine the efficacy of B. longum-En on tumor growth in nude mice. We treated the tumor-bearing nude mice with B. longum-En. The results shown that the growth of primary tumors was potently suppressed by taking orally B. longum-En. Figure 3 and Table 2 showed that tumor growth of mice treated separately with B. longum and B. longum-En was inhibited by 22.5 and 54.4% compared to control group (Po0.01). The inhibitory effect of normal B. longum was lower than that of B. longum carrying endostatin gene.
Treatment with B. longum-En prolongs the survival time of tumor-bearing nude mice
The survival time of tumor-bearing nude mice was prolonged by 36.2% when treated with B. longum-En compared to the control mice, while the survival time was only prolonged by 16% in normal B. longum compared to the control group (Fig 4) . These data suggest that B. longum-En may prolong the survival time of tumorbearing nude mice.
Side effect test
Our study showed that there was no side effect to BALB/c mice following oral treatment with B. longum-En. No abnormalities in the surface, hair, pose nor the walking activity of the animals was observed. The narcosis, hypnosis, sedation, muscle tremor, eye vibration, and pupil dilation of experimental groups was not significantly different in BALB/c mice compared to the control group and to mice treated with B. longum-En (Table 3) .
Se-B. longum-En inhibits the growth of primary tumors in nude mice
In order to enrich selenium to B. longum carrying endostatin gene, we chose sodium selenite (Na 2 SeO 3 , 0.5 mg/mL) to enrich selenium in the B. longum-En strain. Tumor growth was inhibited by 72.5 and 62.2% with the high dose (3 Â 10 10 bacteria/kg) and the middle dose (1.5 Â 10 10 bacteria/kg) of Se-B. longum-En, but was inhibited by 54.4% when treated with the middle dose of B. longum-En (1.5 Â 10 10 bacteria/kg) compared to the control group (Fig 5) . These results suggest that Se-B. longum-En may be more potent than that of B. longum-En in tumor inhibition.
Effects of Se-B. longum-En on NK-cell killing activity and T-cell proliferation
To determine the effects of immune functions following treatment with Se-B. longum-En, NK-cell killing activity and T-cell proliferation in Heps tumor-bearing BALB/c mice were assayed for 15 continuous days after treatment. The NK-cell killing activity of Heps tumor-bearing BALB/c mice treated with the high dose of Se-B. longum-En was improved significantly compared to control group (Po.001, Table 4 ). The improvement of NK killing activity observed in Se-B. longum-En was stronger than that of B. longum-En.
The OD 540 nm readings from spleen cells treated with the serum of the B. longum-En (middle dose), the Se-B. longum-En (high dose) and the Se-B. longum-En (middle dose) were 0.532, 0.600 and 0.574 respectively ( Table 4) . As shown in Table 4 , there were significant differences among the Se-B. longum-En (high dose, Po.001), the Se-B. longum-En (middle dose, Po.05) and the control groups. These results indicate that B. longum-En associated with selenium can stimulate the proliferation of T cell in tumor-bearing mice.
Effects of Se-B. longum-En on activity of IL-2 and TNF-a
To assess whether the activities of IL-2 and TNF-a were affected by treating with Se-B. longum-En, we used an MTT assay to check the levels of IL-2 and TNF-a in the serum of Heps tumor-bearing BALB/c mice of different groups. The activities of IL-2 and TNF-a were clearly promoted by the high dose of Se-B. longum-En compared to the control group in tumor-bearing mice (Table 5 ). B. longum-En promoted the activity of IL-2 and TNF-a, although there was no obvious difference between the B. longum-En and the control group (Table 5) . Some factors including IL-2 and TNF-a were simulated when treated with Se-B. longum-En in tumor-bearing mice.
Discussion
One of the serious obstacles for cancer gene therapy is to deliver anticancer genes specifically into target tumors. Tumor growth and metastasis are angiogenesis-dependent. Angiogenic inducers secreted by tumor cells induce endothelial cells to proliferate, migrate into tumors, and form new vessels. The new intratumoral blood vessels provide nutrients and oxygen to tumor cells and become the paths for tumor cells, allowing entrance into the circulatory system and permitting metastasis into distant organs. Many antiangiogenic factors detected in recent years may inhibit vessel endothelial cell proliferation, induce tumor degradation and apoptosis, and limit tumor migration, but endostatin is an endogenous angiogenic Figure 4 Survival time of tumor-bearing nude mice was prolonged when treated with cyclophosphamide (bar 2, Po.001) and B. longum-En (bar 3, Po.01) compared to PBS control group (bar 1), and B. longum (bar 4) has no obvious difference compared to PBS control group. inhibitor. This suggests that endostatin can specifically suppress endothelial cell proliferation and compete with angiogenic inducers secreted by tumor cells. 1 The inhibition of tumor growth is associated with endostatin levels in the tumor model and is nearly similar in pattern to different models of solid tumors. Additionally, there is a dose-effect relationship between the level of endostatin and tumor inhibition in all tumor tissues. Endostatin has been shown to be an inhibitor of angiogenesis and presents an attractive new strategy for cancer gene therapy. However, poor solubility of recombinant endostatin protein (REP) initially caused high dosage and hampered its widespread application. Bifidobacteria such as B. adolescentis and B. longum can be selected as gene delivery vector. The using of B. longum as a gene therapy vector can solve this difficulty. Moreover, animals and humans can take the B. longum orally. As shown in Figure 3 and Table 2 , the tumor growth inhibitory role of normal B. longum was lower than that of B. longum-En. Also, the B. longum-En has no evident toxicity or side effect on animals in pharmacological and toxicological experiments. These data suggest that the endostatin gene strongly inhibits tumor growth, while the inherent role of B. longum as an antitumor vector of the endostatin gene makes it more efficient to inhibit tumor growth.
Selenium compounds have been found to inhibit carcinogenesis in a variety of animal models. Many reports have shown that selenium supplementation can enhance lymphocyte functions and inhibit solid tumor growth in mice. 21, 22 Recent studies have also indicated that selenium supplements in human diets may reduce carcinogenesis risk. 23 The high dose and the middle dose of Se-B. longum-En can inhibit tumor growth by 72.5 and 62.2% as compared to the control group. However, the middle dose of B. longum-En can inhibit tumor growth by 54.4%. Thus, the inhibitory ratio of Se-B. longum-En is higher than that of B. longum-En.
Some experiments have shown that endostatin has anticancer effects both in vitro and in vivo.
24 B. longum itself also exhibits desirable anticancer effects. 18 Therefore, B. longum carrying endostatin gene can enhance its anticancer effects. Bifidobacterium and selenium could enhance the immune functions synergically in humans. [25] [26] [27] Reid et al 28 have demonstrated that selenium supplementation decreases lung cancer incidence. Our present study also demonstrates that Se-B. longum-En can inhibit tumor growth in nude mice as well as the stimulation of the immune function more efficiently in BALB/c mice. These data show that B. longum can be used as an efficient vector for transporting anticancer genes into animal intestines directly in cancer gene therapy.
